Abigail Brooks, MA

Reau explains the importance of second- and third-line treatment in PBC and the potential implications of no longer having OCA after a negative FDA advisory committee meeting.

Study results suggest C4d is associated with worse renal survival and disease progression to kidney failure in patients with primary IgA nephropathy.

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

Franco describes the importance of discussing pregnancy intentions with patients with liver disease and the need for multidisciplinary comanagement of these patients.

Mathew reviews common reasons for diagnostic delays in PBC, emphasizing the importance of timely identification and prompt treatment for improving patient outcomes.

Janovsky explains the importance of nutrition and dietary interventions in MASH and cirrhosis management, reviewing how providers can discuss both with patients.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

Iordache reviews complications of diagnosing hepatobiliary disease in pregnancy and explains how these patients typically present.

Martinez de Andino reviews key considerations for the management of DGBI with brain-gut behavioral therapy and neuromodulators.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

Low birth weight and being small for gestational age were linked to a greater risk of developing pediatric-onset MASLD and progressive liver disease.

Findings highlight disease burden and ongoing unmet needs in patients with IBS-C and IBS-D, suggesting the benefit of prescription medications on rates of satisfaction and symptom control.

Findings underscore the importance of alcohol cessation in patients with steatotic liver disease, suggesting a synergistic effect between steatosis and alcohol on disease progression.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

Patients with positive endoscopic findings for upper gastrointestinal mucosal damage had a greater risk of developing Parkinson disease compared to those without mucosal damage.

People with chronic liver disease were more likely to experience healthcare barriers and require recurrent acute care compared to those with COPD and/or CVD.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.